A Study About the Use of Omalizumab in the Treatment of Food Allergy and Anaphylaxis

Novartis

Status: Completed

Conditions: Food Hypersensitivity; Anaphylaxis

Study type: Observational

Funder types: Industry

Identifiers

NCT07027163

CIGE025A2010

Details and patient eligibility

About

This was a retrospective, multi-center observational study conducted across four allergy departments in Europe (Berlin, Leipzig, Barcelona, and Basel). The study included patients with immunoglobulin E (IgE)-mediated food allergy who were treated with omalizumab, either as monotherapy or in combination with oral immunotherapy (OIT) between 2002-2022.

Enrollment: 62 patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• A confirmed history of food allergy, either with or without prior anaphylaxis.
• Treated with omalizumab, either as monotherapy or in combination with OIT.

Exclusion criteria

None identified.

Trial design

62 participants in 1 patient group

Omalizumab Cohort

Description:

Adult patients diagnosed with IgE-mediated food allergy who received omalizumab treatment between 2002 and 2022.